How should we handle talimogene laherparepvec (T-VEC)?
5 Nov 2015
How should we handle talimogene laherparepvec (T-VEC)?
Tackling increasing prevalence of cancer and treatment costs
Cancer and the workplace
Preventing cancer in the EU through legislation, education and taxation
System reform needed for UK medicine approval
European Commission: Actions to tackle cancer
How should decision makers assess the value of a medicine?
Message to governments: Prevention is better than cure
Obesity and tobacco use increasing global cancer burden
Lessening the global financial burden of cancer
Challenge of cancer in middle-income countries with an ageing population
Economics of radiation therapy